269 related articles for article (PubMed ID: 8375016)
1. Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent.
Patterson LH
Cancer Metastasis Rev; 1993 Jun; 12(2):119-34. PubMed ID: 8375016
[TBL] [Abstract][Full Text] [Related]
2. Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy.
Patterson LH
Drug Metab Rev; 2002 Aug; 34(3):581-92. PubMed ID: 12214668
[TBL] [Abstract][Full Text] [Related]
3. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
[TBL] [Abstract][Full Text] [Related]
4. DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides.
Smith PJ; Blunt NJ; Desnoyers R; Giles Y; Patterson LH
Cancer Chemother Pharmacol; 1997; 39(5):455-61. PubMed ID: 9054961
[TBL] [Abstract][Full Text] [Related]
5. Effects of AQ4N and its reduction product on radiation-mediated DNA strand breakage.
Ali MM; Symons MC; Taiwo FA; Patterson LH
Chem Biol Interact; 1999 Nov; 123(1):1-10. PubMed ID: 10597898
[TBL] [Abstract][Full Text] [Related]
6. Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer prodrug.
Raleigh SM; Wanogho E; Burke MD; Patterson LH
Xenobiotica; 1999 Nov; 29(11):1115-22. PubMed ID: 10598746
[TBL] [Abstract][Full Text] [Related]
7. DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells.
Hejmadi MV; McKeown SR; Friery OP; McIntyre IA; Patterson LH; Hirst DG
Br J Cancer; 1996 Feb; 73(4):499-505. PubMed ID: 8595165
[TBL] [Abstract][Full Text] [Related]
8. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.
Wilson WR; Denny WA; Pullen SM; Thompson KM; Li AE; Patterson LH; Lee HH
Br J Cancer Suppl; 1996 Jul; 27():S43-7. PubMed ID: 8763844
[TBL] [Abstract][Full Text] [Related]
9. Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1.
Nishida CR; Lee M; de Montellano PR
Mol Pharmacol; 2010 Sep; 78(3):497-502. PubMed ID: 20566689
[TBL] [Abstract][Full Text] [Related]
10. AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo.
McKeown SR; Hejmadi MV; McIntyre IA; McAleer JJ; Patterson LH
Br J Cancer; 1995 Jul; 72(1):76-81. PubMed ID: 7599069
[TBL] [Abstract][Full Text] [Related]
11. AQ4N: a new approach to hypoxia-activated cancer chemotherapy.
Patterson LH; McKeown SR
Br J Cancer; 2000 Dec; 83(12):1589-93. PubMed ID: 11104551
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study.
Albertella MR; Loadman PM; Jones PH; Phillips RM; Rampling R; Burnet N; Alcock C; Anthoney A; Vjaters E; Dunk CR; Harris PA; Wong A; Lalani AS; Twelves CJ
Clin Cancer Res; 2008 Feb; 14(4):1096-104. PubMed ID: 18281542
[TBL] [Abstract][Full Text] [Related]
13. Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry.
Atkinson SJ; Loadman PM; Sutton C; Patterson LH; Clench MR
Rapid Commun Mass Spectrom; 2007; 21(7):1271-6. PubMed ID: 17340571
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.
Patterson LH; McKeown SR; Ruparelia K; Double JA; Bibby MC; Cole S; Stratford IJ
Br J Cancer; 2000 Jun; 82(12):1984-90. PubMed ID: 10864207
[TBL] [Abstract][Full Text] [Related]
15. In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts.
Williams KJ; Albertella MR; Fitzpatrick B; Loadman PM; Shnyder SD; Chinje EC; Telfer BA; Dunk CR; Harris PA; Stratford IJ
Mol Cancer Ther; 2009 Dec; 8(12):3266-75. PubMed ID: 19996276
[TBL] [Abstract][Full Text] [Related]
16. Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.
McCarthy HO; Yakkundi A; McErlane V; Hughes CM; Keilty G; Murray M; Patterson LH; Hirst DG; McKeown SR; Robson T
Cancer Gene Ther; 2003 Jan; 10(1):40-8. PubMed ID: 12489027
[TBL] [Abstract][Full Text] [Related]
17. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs).
Denny WA; Wilson WR
Cancer Metastasis Rev; 1993 Jun; 12(2):135-51. PubMed ID: 8375017
[TBL] [Abstract][Full Text] [Related]
18. Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug.
Raleigh SM; Wanogho E; Burke MD; McKeown SR; Patterson LH
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):763-7. PubMed ID: 9845092
[TBL] [Abstract][Full Text] [Related]
19. Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs.
Patterson LH; Craven MR; Fisher GR; Teesdale-Spittle P
Oncol Res; 1994; 6(10-11):533-8. PubMed ID: 7620222
[TBL] [Abstract][Full Text] [Related]
20. The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.
Trédan O; Garbens AB; Lalani AS; Tannock IF
Cancer Res; 2009 Feb; 69(3):940-7. PubMed ID: 19176397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
